Planning a registrational Phase 3 trial for larsucosterol in alcohol-associated hepatitis (AH) with topline results expected within two years of trial initiation

Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025

CUPERTINO, Calif., May 13, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the first quarter ended March 31, 2025 and provided a business update.

Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025

Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH)

Webcast of earnings call today, March 26 at 4:30 p.m. ET

CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update.

CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. Management will also host a conference call and webcast with investors to discuss the results and provide a business update at 4:30 pm Eastern Time. Details for the call are as follows:

CUPERTINO, Calif., Feb. 4, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, to be held virtually, February 11-12, 2025.

Presentation details are as follows:

Date and time:       

 Tue, Feb 11 at 2:00-2:30 PM ET (Track 5)

Webcast:               

 https://wsw.com/webcast/oppenheimer39/drrx/2823424

The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company's planned Phase 3 trial

CUPERTINO, Calif., Jan. 28, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM Evidence. The full article, entitled, "Larsucosterol for the Treatment of Alcohol-Associated Hepatitis," can be accessed here.

CUPERTINO, Calif., Nov. 25, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announced the sale of its ALZET® line of osmotic pumps to Lafayette Instrument Co. (LIC), a portfolio company of Branford Castle Partners II, L.P., a North-American focused private equity firm.

-     Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation

-     Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET

CUPERTINO, Calif., Nov. 13, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2024 and provided a business update.

CUPERTINO, Calif., Nov. 6, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its third quarter financial results on Wednesday, November 13, 2024. Management will also host a conference call and webcast with investors to discuss financial results and provide a corporate update at 4:30 pm Eastern Time. Details for the call are as follows:

CUPERTINO, Calif., Oct. 17, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury, today announce that it will deliver an oral and two poster presentations at The Liver Meeting 2024, organized by the American Association for the Study of Liver Diseases (AASLD), to be held November 15-19, 2024 in San Diego, California.

- Type B meeting with FDA held under Breakthrough Therapy designation resulted in agreement on key aspects of Phase 3 trial design

- Single Phase 3 trial designed to enroll 200 U.S. patients with a 90-day survival primary endpoint; topline results expected within two years of trial initiation

 - Protocol for Phase 3 trial builds on data from the AHFIRM Phase 2b trial; 30 mg and 90 mg doses of larsucosterol reduced 90-day mortality in U.S. patients by 57% and 58%, respectively, compared with placebo

CUPERTINO, Calif., Sept. 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions such as acute organ injury and cancer, today announced management's participation in the H.C. Wainwright 26th Annual Global Investment Conference to take place September 9-11, 2024 in New York City.

-         FDA Granted Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis

-         Held Type B Meeting with FDA to Discuss Phase 3 Clinical Trial Design

-         Seeking to Initiate Phase 3 Trial in 2024 with Topline Results Expected in 2H 2026

-         Webcast of Earnings Call Today, August 13th at 4:30 p.m. ET

CUPERTINO, Calif., Aug. 13, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2024 and provided a business update.